Importantly, KIT/PDGFRA primary and secondary genotype is relevant for GIST clinical management because it predicts GIST clinical behavior and efficacy from tyrosine kinase inhibitors (TKIs) with KIT inhibitory activity in the first line [12] – imatinib – and in any line of treatment after imatinib failure, including standard second- (sunitinib) and third-line treatments (regorafenib) [13–17]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.